Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International reports news on cord blood banking, cord tissue cryopreservation, cellular processing and cryogenic storage. The company operates a private family-use cord blood bank, maintains a public banking program with Duke University, and holds exclusive rights to the PrepaCyte-CB cord blood processing technology.
Recurring updates cover financial results from processing and storage fees, product and public banking revenue, FACT and AABB accreditation matters, FDA-registered and cGMP-/cGTP-compliant operations, and ExtraVault biostorage and distribution services for biopharmaceutical companies and healthcare institutions. Company news also includes dividend actions, credit and capital-allocation decisions, and NYSE American continued-listing compliance developments.
Cryo-Cell (NYSE American: CCEL) announced that NYSE American accepted its compliance plan and granted a compliance period through September 9, 2027. The Company was previously noncompliant due to a stockholders' deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The acceptance allows CCEL’s common stock to remain listed and traded while the company implements the plan, but the company warned there is no assurance it will regain compliance by the deadline and that delisting proceedings could follow if progress is insufficient.
Cryo-Cell stores over 250,000 cord blood and tissue specimens and highlights regulatory accreditations and proprietary processing technology.
Cryo-Cell International (NYSE American: CCEL) received renewed FACT re-accreditation for Cord Blood Collection, Banking, and Release for Administration, effective through April 3, 2029. This extends continuous FACT validation since the company’s original 2014 accreditation, positioning Cryo-Cell with the longest independently validated quality track record among U.S. private cord blood banks.
The FACT award follows verification against NetCord-FACT Standards and complements Cryo-Cell’s FDA registration, cGMP/cGTP compliance, AABB accreditation, state licenses, NMDP network status, and exclusive rights to PrepaCyte-CB processing technology.
Cryo-Cell International (NYSE American: CCEL) reported fiscal Q1 2026 results for the quarter ended February 28, 2026. Revenue was $7.68 million versus $7.97 million a year earlier. The company reported net income of approximately $47,000 ($0.01 per share) versus $283,000 ($0.03) in Q1 2025. Processing and storage revenue was $7.64 million; public banking revenue declined to about $1,400. Cryo-Cell continues to store over 250,000 cord blood and tissue specimens and maintains FDA registration, cGMP/cGTP compliance and AABB/FACT accreditations.
Cryo-Cell International (NYSE American: CCEL) received a continued listing notice from NYSE American on March 12, 2026 for noncompliance with Section 1003(a).
The notice cites a stockholders' deficit as of November 30, 2025 and net losses in two of the last three fiscal years. Trading will continue while the company submits a plan to regain compliance, typically within an 18-month remediation period if accepted.
Cryo-Cell (NYSE American: CCEL) reported fiscal 2025 results for the year ended November 30, 2025. Consolidated revenue was $31.6 million versus $32.0 million a year earlier. The company recorded a $4.4 million impairment in Q4 and a $2.4 million net loss (loss of $0.30 per share).
Processing and storage fees comprised nearly all revenue; public banking and product revenue declined year-over-year. The company highlighted its regulatory accreditations, exclusive PrepaCyte-CB processing rights, and long-standing public bank partnership with Duke University.
Cryo-Cell International (NYSE:CCEL) reported fiscal third quarter results for the period ended August 31, 2025. Consolidated revenue was $7.83 million, down slightly from $8.07 million a year earlier. The company reported net income $749,000, or $0.09 per share, versus $1.05 million, or $0.13 per share, in the prior-year quarter.
Cryo-Cell reiterated operational credentials: FDA registration, cGMP/cGTP compliance, AABB and FACT accreditations, exclusive rights to PrepaCyte-CB processing, and more than 500,000 private clients across 87 countries.
Cryo-Cell International (NYSE American:CCEL), the world's first private cord blood bank, announced the suspension of its quarterly cash dividend for Q3 2025 due to lower-than-expected profitability. The company, which has stored stem cells for over 500,000 parents from 87 countries, maintains partnerships with Duke University and operates cord blood donation sites at prominent hospitals.
Founded in 1989, Cryo-Cell has achieved significant milestones including FDA registration, cGMP/cGTP compliance, and FACT accreditation. The company has expanded its services through initiatives like ExtraVault for biostorage solutions and holds exclusive rights to PrepaCyte-CB technology. Future dividend declarations will depend on financial performance, capital requirements, and strategic priorities.
Cryo-Cell International (NYSE American:CCEL), the world's first private cord blood bank, reported its fiscal Q2 2025 financial results. The company recorded revenue of $7.9 million, a slight 1% decrease from $8.0 million in Q2 2024. Net income decreased to $356,000 ($0.04 per share) from $656,000 ($0.08 per share) year-over-year.
The company's revenue breakdown included $7.87 million in processing and storage fees, $43,000 in public banking revenue, and $14,000 in product revenue. Cryo-Cell maintains a significant presence in the cord blood banking industry, serving over 500,000 parents from 87 countries and operating a public banking program in partnership with Duke University that has facilitated more than 700 transplants.
Cryo-Cell International (CCEL), the pioneering private cord blood bank, has announced a reduced quarterly cash dividend of $0.15 per share of common stock. The dividend will be paid on May 30, 2025, to shareholders of record as of May 21, 2025. The company cited the current economic environment and other capital allocation alternatives as reasons for the dividend reduction. The Board of Directors will continue to evaluate the dividend policy, with no guarantee of future dividend payments.
[ "Maintaining dividend payments despite economic challenges", "Clear commitment to returning value to shareholders" ]Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has reported its fiscal Q1 2025 financial results. The company's revenue increased to $7.97 million from $7.85 million in Q1 2024, primarily consisting of $7.87 million in processing and storage fees.
Net income decreased to $283,000 ($0.03 per share) compared to $556,000 ($0.07 per share) in the same period last year. The company serves over 500,000 parents from 87 countries and operates a public banking program with Duke University that has provided cord blood for more than 600 transplantations.